• Dr. Prabha Nagareddy obtained his B. Pharm and M. Pharm degrees from Bangalore University (1998) and RGUHS (2001) respectively from Bangalore, India. He then spent a year working as a pharmacologist in a pharmaceutical company before moving to Canada. In the fall of 2002, he joined the laboratory of Dr. John McNeill at the University of British Columbia and received his MSc (2004) and PhD (2009) degrees. Since his graduate training, Dr. Nagareddy is interested in understanding the molecular pathways that contribute to accelerated cardiovascular disease in diabetes. His MSc thesis research was primarily focused on studying the aberrant signaling mechanisms in blood vessels that contributed to impaired endothelial function, attenuated pressor responses to vasoactive agents and depressed blood pressure in animal models of type I diabetes. His doctoral research was aimed at understanding the mechanisms of insulin resistant hypertension in type 2 diabetes. He specifically studied the role of matrix metalloproteinase (MMPs) and the MMP-dependent epidermal growth factor receptor transactivation pathway in the development of insulin-resistant hypertension. During the entire time of his graduate research he was supported by funding from the Heart and Stroke Foundation of Canada and Michael Smith Foundation for Health Research.

    Upon completing his PhD, Dr. Nagareddy moved to New York to commence a postdoctoral fellowship with Dr. Ira Goldberg at Columbia University. During this time, he was funded by a prestigious Canadian Institute of Health Research Fellowship. At Columbia, his postdoctoral work broadly focused on two main themes; mechanisms of accelerated atherosclerosis in diabetes and identification of the origins of adipose tissue macrophages in type 2 diabetes/ obesity. In collaborations with Drs. Alan Tall, Andrew Murphy and Ed Fisher, he discovered a novel role for the damage associated molecular patterns S100A8/A9 in hyperglycemia-accelerated atherosclerosis in diabetes. These findings which were published in the journal Cell Metabolism in 2013 laid the foundation for his future research work and a long-standing collaboration with Dr. Andrew Murphy at Baker IDI Heart and Diabetes Institute in Melbourne, Australia.

    In 2013, Dr. Nagareddy joined the laboratory of Dr. Susan Smyth at the University of Kentucky (UK) and continued to work on exploring the mechanisms of myelopoiesis in obesity and its impact on adipose tissue inflammation, insulin resistance and cardiovascular disease. This work which also was the basis of his successful K99/R00 grant application specifically targeted the pathways that regulate myelopoiesis in the bone marrow (sterile inflammation). The findings from these studies were published once again in Cell Metabolism (2014) accompanied by editorials and cover page highlights. Lately in collaboration with Dr. Abdel-Latif, an interventional cardiologist at the UK and Andrew Murphy at Baker, he is studying the mechanisms of neutrophilia in conditions of acute myocardial ischemia. Further, in collaboration with his wife Dr. Beatriz Hanaoka, a Rheumatologist at UAB, he is exploring the molecular pathways that contribute to increased cardiovascular disease risk in Rheumatoid Arthritis (RA) patients.

    In the May of 2016, he was recruited as an Assistant Professor by the Department of Nutrition Sciences at The University of Alabama at Birmingham. With these training experiences, he has expanded his research in exploring similar pathways that promote/mediate sterile inflammation in different disease settings such as acute myocardial ischemia, traumatic brain injury, stroke, rheumatoid arthritis etc.

    His outside interests include reading, cooking, travelling and most importantly time with his wife and 2-year-old triplet girls.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 S100A8/A9 in Myocardial Infarction.Methods in Molecular Biology.  1929:739-754. 2019
    2018 Chronic sympathetic driven hypertension promotes atherosclerosis by enhancing hematopoiesis.Haematologica2018
    2018 Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis.Clinical Science.  132:1889-1899. 2018
    2018 It's reticulated: the liver at the heart of atherosclerosis.Journal of Endocrinology.  238:R1-R11. 2018
    2018 Cathelicidin Related Antimicrobial Peptide (CRAMP) Enhances Bone Marrow Cell Retention and Attenuates Cardiac Dysfunction in a Mouse Model of Myocardial Infarction.Stem Cell Reviews and Reports.  14:702-714. 2018
    2018 Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis.European Heart Journal.  39:2158-2167. 2018
    2018 SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice.Atherosclerosis.  271:166-176. 2018
    2018 Rad GTPase deletion attenuates post-ischemic cardiac dysfunction and remodeling.JACC: Basic to Translational Science.  3:83-96. 2018
    2017 Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.Journal of Clinical Investigation.  127:2133-2147. 2017
    2015 Pharmacological Elevation of Circulating Bioactive Phosphosphingolipids Enhances Myocardial Recovery After Acute Infarction.Stem Cells Translational Medicine.  4:1333-1343. 2015
    2015 Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice.Arteriosclerosis, Thrombosis, and Vascular Biology.  35:102-110. 2015
    2014 Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity.Cell Metabolism.  19:821-835. 2014
    2014 A novel role for bioactive lipids in stem cell mobilization during cardiac ischemia: new paradigms in thrombosis: novel mediators and biomarkers.Journal of Thrombosis and Thrombolysis.  37:24-31. 2014
    2013 Inflammation and thrombosis in cardiovascular disease.Current opinion in hematology.  20:457-463. 2013
    2013 Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children.Atherosclerosis.  229:79-85. 2013
    2013 Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice.Circulation Research.  112:1456-1465. 2013
    2013 Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis.Cell Metabolism.  17:695-708. 2013
    2012 Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway.Endocrinology.  153:5143-5149. 2012
    2012 Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats.British Journal of Pharmacology.  165:705-715. 2012
    2010 GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats.Cardiovascular Research.  87:177-186. 2010
    2009 Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis.Cardiovascular Research.  84:368-377. 2009
    2009 Selective inhibition of protein kinase C beta(2) attenuates inducible nitric oxide synthase-mediated cardiovascular abnormalities in streptozotocin-induced diabetic rats.Diabetes.  58:2355-2364. 2009
    2009 Chronic inhibition of inducible nitric oxide synthase ameliorates cardiovascular abnormalities in streptozotocin diabetic rats.European Journal of Pharmacology.  611:53-59. 2009
    2008 Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats.Cardiovascular Research.  79:322-330. 2008
    2007 N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats.Cardiovascular Research.  73:770-782. 2007
    2006 Gonadectomy prevents endothelial dysfunction in fructose-fed male rats, a factor contributing to the development of hypertension.AJP - Heart and Circulatory Physiology.  291:H3058-H3064. 2006
    2006 Antioxidant N-acetylcysteine restores myocardial Mn-SOD activity and attenuates myocardial dysfunction in diabetic rats.European Journal of Pharmacology.  544:118-125. 2006
    2006 N-acetylcysteine prevents nitrosative stress-associated depression of blood pressure and heart rate in streptozotocin diabetic rats.Journal of Cardiovascular Pharmacology.  47:513-520. 2006
    2006 Withania somnifera improves bone calcification in calcium-deficient ovariectomized rats.Journal of Pharmacy and Pharmacology.  58:513-519. 2006
    2006 Antioxidant N-acetylcysteine restores systemic nitric oxide availability and corrects depressions in arterial blood pressure and heart rate in diabetic rats.Free Radical Research.  40:175-184. 2006
    2005 Assessment of experimental osteoporosis using CT-scanning, quantitative X-ray analysis and impact test in calcium deficient ovariectomized rats.Journal of Pharmacological and Toxicological Methods.  52:350-355. 2005
    2005 Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes.AJP - Heart and Circulatory Physiology.  289:H2144-H2152. 2005
    2005 Oral administration of sodium tungstate improves cardiac performance in streptozotocin-induced diabetic rats.Canadian Journal of Physiology and Pharmacology.  83:405-411. 2005
    2003 Effect of Praval bhasma (Coral calx), a natural source of rich calcium on bone mineralization in rats.Pharmacological Research.  48:593-599. 2003

    Research Overview

  • The research in my lab is broadly focused on studying how the so called “cardiovascular risk factors” contribute to cardiovascular disease. We specifically examine the role of diabetes, obesity, smoking, rheumatoid arthritis, high salt diet etc. on atherosclerosis and /or ischemic heart disease. Currently, we are investigating 1) how reticulated platelets impact atherothrombosis in models of diabetes, 2) smoking-induced leukocytosis and its role in accelerated atherosclerosis and 3) pathways that regulate granulopoiesis (cardiac inflammation) in acute myocardial infarction (MI) and its impact on cardiac remodeling and function.
  • Full Name

  • Prabhakara Nagareddy
  • Fax

  • 205-975-4065